The fund seeks capital appreciation in the long term by investing in companies across any size outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests significantly in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary that are relevant to the fund’s investment theme of the genomics revolution.

The team favors companies that are focused on extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.

In selecting securities for the portfolio, the research team prefers companies that are capitalizing on disruptive innovation or that are enabling the further development of a theme in the markets in which they operate.

Also, the research team integrates environmental, social and governance factors as part of its process.

In addition, the team employs both top-down and bottom-up analysis to select investments for the fund.

In its top down approach, the team utilizes the framework of the United Nations Sustainable Development Goals to integrate ESG considerations into its research and investment process.

As part of its bottom up approach, the team evaluates the potential of individual companies, while integrating ESG considerations into that process.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

The portfolio holds between 40 and 60 companies.

However, the fund’s net assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises.

The fund’s investments in foreign equity securities will be in both developed and emerging markets.

Additionally, the fund will be concentrated in securities of issuers having their principal business activities in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry.

Other industries in the health care sector include medical laboratories and research and drug manufacturers.

The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts and Global Depositary Receipts.

The fund is classified as a non-diversified investment company, which means that it may invest a high percentage of its assets in a limited number of issuers.

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.

As part of its strategy, the fund employs a passive or indexing approach.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests significantly in the securities of the Underlying Index.

The Underlying Index is designed to provide exposure to exchange-listed companies in developed markets that facilitate the demographic trend of longer average life spans and the aging of the global population, including but not limited to companies involved in biotechnology, medical devices, pharmaceuticals, senior living facilities and specialized health care services.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund seeks to replicate the composition of the benchmark index, holding each security in approximately the same proportion as its weighting in the Index.

However, the fund may utilize a representative sampling strategy when there are practical difficulties or substantial costs involved in compiling a portfolio of equity securities to replicate the Underlying Index.

The fund concentrates its investments in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated.

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.

As part of its strategy, the fund employs a passive or indexing approach.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests significantly in the securities of the Underlying Index and in American Depositary Receipts and Global Depositary Receipts based on the securities in the Underlying Index.

The Underlying Index is designed to provide exposure to exchange-listed companies in developed markets that provide products and services that facilitate physical wellness through active and healthy lifestyles, including but not limited to companies involved in fitness equipment, fitness technology, athletic apparel, nutritional supplements, and organic/natural food offerings.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund seeks to replicate the composition of the benchmark index, holding each security in approximately the same proportion as its weighting in the Index.

However, the fund may utilize a representative sampling strategy when there are practical difficulties or substantial costs involved in compiling a portfolio of equity securities to replicate the Underlying Index.

The fund concentrates its investments in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated.

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

As part of its strategy, the fund employs a passive or indexing approach.

Next, the research team invests significantly in the component securities of its Underlying Index and in investments that have economic characteristics that are substantially identical to the component securities of its Underlying Index.

The Underlying Index is composed of global equities in the healthcare sector. 
The team utilizes a representative sampling indexing strategy that involves investing in a representative sample of securities that collectively has an investment profile similar to that of an applicable underlying index.

Also, the team evaluates companies based on factors such as market capitalization and industry weightings.

In addition, the team also assesses a company’s return variability and yield, and liquidity characteristics.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund may or may not hold all of the securities in the Underlying Index.

The fund will concentrate its investments in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated.

Also, the fund may invest up to 20% of its net assets in certain futures, options and swap contracts, cash and cash equivalents, including shares of money market funds advised by BFA or its affiliates, as well as in securities not included in the Underlying Index.

The fund may lend securities representing up to one-third of the value of its net assets.

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests significantly in components of the Underlying Index, depositary receipts, including American depositary receipts, representing such components and securities underlying depositary receipts in the Underlying Index.

The Underlying Index is designed to measure the equity market performance of emerging market companies as being in the health technology or health services industries.

The Underlying Index includes companies in the pharmaceuticals, biotechnology, medical specialties, managed health care, hospital/nursing management, medical/nursing services and services to the health industry businesses.

The team utilizes a representative sampling strategy that involves investing in a representative sample of securities that collectively have an investment profile similar to the Underlying Index.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

To the extent the Underlying Index is concentrated in a particular industry, the fund is estimated to be concentrated in that industry.

The fund may invest up to 20% of its net assets in instruments that are not included in the Underlying Index.

Also, the fund may engage in securities lending.

The fund is non-diversified.

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests significantly in components of the Underlying Index, depositary receipts, including American depositary receipts, representing such components and securities underlying depositary receipts in the Underlying Index.

The Underlying Index is designed to measure the equity market performance of Chinese companies in the healthcare sector.

The securities eligible for inclusion in the Underlying Index include all types of publicly issued shares of Chinese issuers, such as A-Shares, B-Shares, H-Shares, P-Chips and Red Chips.

The team utilizes a representative sampling strategy that involves investing in a representative sample of securities that collectively have an investment profile similar to the Underlying Index.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

To the extent the Underlying Index is concentrated in a particular industry, the fund is estimated to be concentrated in that industry.

The fund may invest up to 20% of its net assets in instruments that are not included in the Underlying Index.

Also, the fund may engage in securities lending.

The fund is non-diversified.

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.

The sub-adviser’s investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

As part of its strategy, the fund employs a passive management or indexing approach to track the performance of the Index.

Next, the research team invests significantly in the component securities and depositary receipts that make up the Index.

The Index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China’s pharmaceutical and biotech related industries.

The Index includes pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers or distributors of biopharma products, and biopharma service providers.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund seeks to replicate the composition of the benchmark index, holding each security in approximately the same proportion as its weighting in the Underlying Index.

In addition, the fund employs a representative sampling strategy, which means that the fund will hold a portfolio of securities with generally the same risk and return characteristics of the Index.

To the extent the Index concentrates in the securities of a particular industry or group of related industries, the fund will concentrate its investments to approximately the same extent as the Index.

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

As part of its strategy, the fund employs a passive or indexing investment approach to approximate the investment performance of the Index by investing in a portfolio of securities that generally replicates the Index.

Next, the research team invests significantly in securities that comprise the benchmark index.

The Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry.

Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund may concentrate its investments in a particular industry or group of industries to the extent that the Index concentrates in an industry or group of industries.

Also, the fund is classified as a non-diversified fund, and, therefore, may invest a greater percentage of its assets in a particular issuer.

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

As part of its strategy, the fund employs a passive or indexing investment approach to approximate the investment performance of the Index by investing in a portfolio of securities that generally replicates the Index.

Next, the research team invests significantly in securities that comprise the Index.

The Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry.

Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund may concentrate its investments in a particular industry or group of industries to the extent that the Index concentrates in an industry or group of industries.

Also, the fund is classified as a non-diversified fund, and, therefore, may invest a greater percentage of its assets in a particular issuer.